NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/05/2026
Voltar para busca
Dado oficial do USPTO
EXUMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
05/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
11/08/2022
Data de registro
05/05/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/05/2026
Última transação
05/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
15/12/2024
Primeiro uso no comércio
15/12/2024
Código do desenho
4
Tipo de titular
03
Localização do titular
West Palm Beach, FL, US
Examinador
LAPTER, ALAIN J
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Exuma Biotech Corp.
Representantes
Alison M. Caless CANTOR COLBURN LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for human purposes in the nature of pharmaceutical preparations for gene and cell therapy, immunotherapy and the treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, and infectious diseases; biological preparations for medical treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, gene and cell therapy, and infectious diseases for humans and animals; medical biological tissue cultures and viruses for the prevention and treatment of cancer for humans and animals; drug products in the nature of pharmaceutical preparations for immunotherapy and the treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, and infectious diseases for humans and animals
Classe 40
Custom manufacturing of medical products in the nature of biological tissue, blood, viruses, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy, including gene therapy, CAR T cell therapy, and cell therapy; custom manufacturing of biological preparations for the treatment of cancer
Classe 42
Bacteriological research; biological research; medical and scientific research, namely, conducting clinical trials for others; medical research; virological research; medical laboratory services; scientific research; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs, namely, processing blood to isolate leukocytes for the creation of immunotherapies; scientific and medical research and development of pharmaceutical preparations and drugs; computer programming in relation to medicine and medical research; research in the field of stem cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
05/05/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/04/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/04/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
14/04/2026
IUAF
USE AMENDMENT FILED
07/11/2025
EISU
TEAS STATEMENT OF USE RECEIVED
07/11/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/05/2025
EX2G
SOU EXTENSION 2 GRANTED
06/05/2025
EXT2
SOU EXTENSION 2 FILED
06/05/2025
EEXT
SOU TEAS EXTENSION RECEIVED
06/05/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/11/2024
EX1G
SOU EXTENSION 1 GRANTED
06/11/2024
EXT1
SOU EXTENSION 1 FILED
06/11/2024
EEXT
SOU TEAS EXTENSION RECEIVED
06/11/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/05/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/02/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
05/02/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/02/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
05/02/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/02/2024
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
05/02/2024
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
16/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/01/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/12/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/12/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/12/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
01/09/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
01/09/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/06/2023
GNRT
NON-FINAL ACTION E-MAILED
02/06/2023
CNRT
NON-FINAL ACTION WRITTEN
02/06/2023
DOCK
ASSIGNED TO EXAMINER
31/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
31/08/2022
NWAP
NEW APPLICATION ENTERED
15/08/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EXUMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.